Joerg Albrecht

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5266855/publications.pdf

Version: 2024-02-01

41	1,253	759233 12	501196 28
papers	citations	h-index	g-index

44	44	44	1731
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Another antiâ€interleukin (<scp>IL</scp>)â€17 inhibitor: is there an advantage of blocking <scp>ILâ€17A</scp> and <scp>ILâ€17F</scp> ?. British Journal of Dermatology, 2022, 186, 603-604.	1.5	0
2	Guidebook to Dermatological Diagnosis. SusanBurgin. New York, NY: McGraw Hill, 2021; 624 pp. ISBN: 978â€0071738750. Price Â£56Â·34.. British Journal of Dermatology, 2022, 186, 914-915.	1.5	0
3	The Power of Topical Steroids. JAMA Dermatology, 2022, 158, 727.	4.1	1
4	Dapsoneâ€induced agranulocytosis: symptoms may alert more reliably than the current blood monitoring protocol. British Journal of Dermatology, 2021, 184, 962-963.	1.5	3
5	At 180Âdays hidradenitis suppurativa readmission rate is comparable to heart failure: Analysis of the nationwide readmissions database. Journal of the American Academy of Dermatology, 2021, , .	1.2	1
6	Longâ€term efficacy: the new gold standard?. British Journal of Dermatology, 2021, 185, 1086.	1.5	0
7	Viability considerations in implementing same-class topical steroid substitution. Journal of the American Academy of Dermatology, 2020, 83, e441.	1.2	0
8	Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology. Journal of the American Academy of Dermatology, 2020, 83, 691-699.	1.2	2
9	Rifampin and clindamycin are safe long-term: Response to â€œNorth American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical managementâ€. Journal of the American Academy of Dermatology, 2019, . . .	1.2	2
10	Who likes to perform the Psoriasis Area and Severity Index?. British Journal of Dermatology, 2019, 180, 260-261.	1.5	0
11	Understanding cutaneous lupus erythematosus: a step forward. British Journal of Dermatology, 2019, 180, 1292-1293.	1.5	1
12	Methodology of Evaluating the Laboratory Monitoring of Terbinafine Therapy. JAMA Dermatology, 2019, 155, 756.	4.1	1
13	The recommendations about laboratory monitoring on isotretinoin are reasonable, but the patient numbers cannot prove it. Journal of the American Academy of Dermatology, 2019, 85, e367.	1.2	0
14	Rifampicin alone may be enough: is it time to abandon the classic oral clindamycinâ€“rifampicin combination for hidradenitis suppurativa?. British Journal of Dermatology, 2019, 180, 949-950.	1.5	15
15	Clindamycin alone may be enough. Is it time to abandon rifampicin for hidradenitis suppurativa? Reply from the authors. British Journal of Dermatology, 2019, 180, 1262-1263.	1.5	0
16	Professor Sidney Barski (1918â€“2018). British Journal of Dermatology, 2019, 180, 234-235.	1.5	0
17	Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. Journal of the American Academy of Dermatology, 2019, 80, 577-578.	1.2	7
18	Longâ€term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A Critically Appraised Topic. British Journal of Dermatology, 2019, 180, 749-755.	1.5	35

#	Article	IF	Citations
19	Optimizing case reports and case series: guidance on how to improve quality. British Journal of Dermatology, 2018, 178, 1257-1262.	1.5	6
20	When to switch biologics: some answers, but lots of questions too. British Journal of Dermatology, 2018, 178, 20-20.	1.5	0
21	Terbinafine-induced liver injury may be asymptomatic: need for regular monitoring: reply from the authors. British Journal of Dermatology, 2018, 178, 808-809.	1.5	0
22	Development of resistance to Mycobacterium tuberculosis is manageable in hidradenitis suppurativa. Response to â€˜Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?â€™. British Journal of Dermatology, 2018, 178, 300-300.	1.5	4
23	Put the ducks in a row - which biologic to use first?. British Journal of Dermatology, 2018, 179, 241-242.	1.5	0
24	Paternal drug exposure: plenty of confounders, few conclusions. British Journal of Dermatology, 2017, 176, 847-848.	1.5	1
25	Not every patient needs a triglyceride check, but all can get pancreatitis: a systematic review and clinical characterization of isotretinoin-associated pancreatitis. British Journal of Dermatology, 2017, 177, 960-966.	1.5	28
26	Switching expensive drugs with frequently diminishing value. British Journal of Dermatology, 2017, 177, 338-339.	1.5	1
27	Prior authorizations for dermatologic medications: An American Academy of Dermatology survey of US dermatology providers and staff. Journal of the American Academy of Dermatology, 2017, 77, 784-786.	1.2	9
28	Positive about negative: no need for a pink cloud of fluff and justifications. British Journal of Dermatology, 2017, 177, 1-3.	1.5	1
29	Clinical presentation of terbinafineâ€induced severe liver injury and the value of laboratory monitoring: a Critically Appraised Topic. British Journal of Dermatology, 2017, 177, 1279-1284.	1.5	34
30	A new option on the horizon for the treatment of psoriasis: it is needed, but not at any price. British Journal of Dermatology, 2016, 174, 1183-1184.	1.5	0
31	The state and consequences of dermatology drug prices in the United States. Journal of the American Academy of Dermatology, 2016, 75, 603-605.	1.2	15
32	Preferred reporting of case series in surgery; the PROCESS guidelines. International Journal of Surgery, 2016, 36, 319-323.	2.7	351
33	Clinical trials in theBJD: more meat, less salami. British Journal of Dermatology, 2015, 173, 1353-1354.	1.5	6
34	The Reach of the 340B Drug Pricing Program. JAMA Dermatology, 2015, 151, 923.	4.1	5
35	A survey of case reports and case series of therapeutic interventions in theArchives of Dermatology. International Journal of Dermatology, 2009, 48, 592-597.	1.0	21
36	The role of case reports in evidence-based practice, with suggestions for improving their reporting. Journal of the American Academy of Dermatology, 2009, 60, 412-418.	1.2	59

#	Article	IF	Citations
37	Skin involvement and outcome measures in systemic autoimmune diseases. Clinical and Experimental Rheumatology, 2006, 24, S52-9.	0.8	17
38	The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus. Journal of Investigative Dermatology, 2005, 125, 889-894.	0.7	376
39	Case reports and case series from had significant impact on medical literature. Journal of Clinical Epidemiology, 2005, 58, 1227-1232.	5.0	135
40	Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus, 2004, 13, 839-849.	1.6	103
41	The meaning of â€œsafe and effectiveâ€• Journal of the American Academy of Dermatology, 2003, 48, 144-147.	1.2	11